Ubs Ag v. China Metal Recycling (Holdings) Limited (in Liquidation) and Another
Read the full judgment text of FAMV 251/2023 on BabelCite. This Court of Final Appeal judgment was delivered on 5 September 2023 before Ribeiro Ag CJ, Lam PJ, Bokhary NPJ.
Civil procedure – leave to appeal – originating process – winding-up proceedings – fraudulent trading claim under section 275 of the Companies (Winding-up and Miscellaneous Provisions) Ordinance (Cap 32) – whether commencement of such claim by writ of summons instead of by misfeasance summons under rule 58(1) of the Companies Winding-up Rules renders the writ a nullity or merely a curable formal defect or irregularity – whether rule 209(1) of the Companies Winding-up Rules (the curative provision) applies to cure such non-compliance – whether curative relief would deprive the defendant of an accrued limitation defence under the Limitation Ordinance (Cap 347) – Companies Winding-up Rules rule 209(1) – Companies Winding-up Rules rule 58(1) – Limitation Ordinance section 26(1) – Rules of the High Court Order 1 rule 2(2) – Rules of the High Court Order 2 rules 1(1), 1(3) and 2(1) – Phillips v McGregor-Paterson – Re Continental Assurance Co of London plc (in liq) (No 2) – Re Taunton Logs Ltd – Allen v Mittal – Re SMU Investments Ltd – Re Baillies Ltd (in liq) – China Medical Recycling (Holdings) Limited (In Liquidation) wound up on 26 February 2015 on the ground of large-scale fraud perpetrated by Chairman and CEO Mr Chun Chi Wai on HKEX and investors – UBS AG acted as joint sponsor, sole global coordinator, sole lead manager and sole bookrunner for the June 2009 IPO – UBS Europe SE (wholly-owned subsidiary) subscribed for notes and warrants and reaped substantial profits on the IPO – Liquidators issued writ on 25 July 2019 alleging dishonest assistance, knowing receipt and fraudulent trading under CO s 275 – writ served on UBS AG on 23 June 2020 within time on any view – UBS AG filed defence on 24 December 2020 without raising any WU r 58(1) objection and actively participated in proceedings – Liquidators subsequently issued winding-up summons on 12 May 2021 as a precautionary measure after becoming aware of the rule 58(1) point from Ng J's decisions in China Medical Technologies, Inc v Wu Xiaodong and related proceedings – UBS AG then raised originating process objection and sought to strike out the writ – striking out succeeded before Anthony Chan J who held non-compliance with WU r 58(1) rendered the writ a nullity not curable by RHC's curative provisions (O 2 r 1(3) and O 2 r 2(1)) given O 1 r 2(2) excludes winding-up proceedings from RHC – Court of Appeal reversed, holding that commencing the claim by writ instead of summons is a 'formal defect' or 'irregularity' curable under WU r 209(1), following Phillips v McGregor-Paterson on the equivalent UK rule – no accrued limitation defence because writ was issued in time and limitation was not pleaded in the defence – no substantial injustice to UBS AG from granting curative relief – the knowledge and deliberateness of the choice of wrong process was a factor in discretion but not decisive given UBS AG's extended participation without objection – whether proposed grounds of appeal concerning applicability of WU r 209(1), the rule's power to override substantive limitation rights, and the scope of 'substantial injustice' are reasonably arguable – held none is reasonably arguable – the proposition that non-compliance with WU r 58(1) rendered the writ an incurable nullity is indefensible – questions 2 and 3 both premised on an accrued limitation defence that cannot be made out – the 'or otherwise' ground based on the deliberateness of the choice does not warrant interference with the Court of Appeal's discretionary exercise – application for leave to appeal dismissed with costs – the case concerns whether the RHC's curative provisions apply, and the corresponding application of WU r 209(1), where proceedings for a winding-up matter (a CO s 275 fraudulent trading claim) were commenced by writ instead of by the required misfeasance summons, and whether such non-compliance renders the proceedings a nullity or merely a curable irregularity.
Legal issues: Whether leave to appeal should be granted on questions concerning applicability of WU r 209(1) to cure non-compliance with WU r 58(1) and alleged loss of limitation defence
Outcome: Application for leave to appeal dismissed with costs; none of the proposed points is reasonably arguable
Cites 5 cases
|
FAMV No. 251 of 2023 [2023] HKCFA 29 IN THE COURT OF FINAL APPEAL OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION MISCELLANEOUS PROCEEDINGS NO. 251 OF 2023 (CIVIL) (ON APPLICATION FOR LEAVE TO APPEAL FROM CACV NO. 384 OF 2022) ________________________
________________________
__________________________________ REASONS FOR DETERMINATION __________________________________ Mr Justice Ribeiro Ag CJ: 1.At the hearing, this application for leave to appeal was dismissed with costs for reasons which we now provide. A. The background 2.China Metal Recycling (Holdings) Limited (“CMR”) was listed on the Hong Kong Stock Exchange (“HKEX”) on 22 June 2009, raising HK$1.7Bn on its Initial Public Offering (“IPO”). Mr Chun Chi Wai (“Chun”) was a director, its Chairman and CEO. UBS AG was one of the joint sponsors, the sole global coordinator, sole lead manager and sole bookrunner for that IPO. UBS AG had provided financial advice to CMR prior to the listing and had acted as the exclusive placement agent in connection with certain notes and warrants issued by CMR. UBS Europe SE, a wholly-owned subsidiary of UBS AG, had subscribed for some of those notes and warrants, and on the successful IPO, reaped substantial profits from those instruments either for itself or for UBS AG. 3.Some four years after the listing, on 26 July 2013, the Securities and Futures Commission petitioned to wind up CMR and the 2nd Plaintiffs (“Ps”) were appointed as provisional liquidators. CMR was wound up on 26 February 2015 on the ground that large-scale fraud had been perpetrated by Chun on HKEX and investors. Ps were appointed Liquidators on 14 May 2015. 4.They issued the writ on 25 July 2019 and served it on UBS AG in Hong Kong on 23 June 2020. UBS Europe SE was served in Germany as a necessary or proper party to the Hong Kong action against UBS AG. In this application, we are concerned only with the action against UBS AG. 5.Ps allege that UBS AG had acted dishonestly by permitting or procuring Chun to make representations to HKEX and potential investors in the listing application which overstated CMR’s revenues and profits and which UBS knew or suspected were false, and by continuing to assist CMR in that application without making the necessary investigations, enquiries or disclosures.[1] 6.Ps’ claim against UBS AG is framed in terms of dishonest assistance and knowing receipt in connection with Chun’s breaches of fiduciary duty. They claim that UBS AG is liable to disgorge fees and commissions received and the sums of HK$79M and HK$244M representing the proceeds of the notes and warrants. Ps’ further or alternative claim is for fraudulent trading under section 275 of the Companies (Winding-up and Miscellaneous Provisions) Ordinance[2] (“CO s 275” and “the Ordinance”), alleging that UBS AG was knowingly a party to Chun’s carrying on of the business of CMR with intent to defraud the company’s creditors and/or for a fraudulent purpose. Ps claim that UBS AG is liable under CO s 275 for all or any of the debts or other liabilities of CMR.[3] B. The procedural history 7.The writ containing the fraudulent trading claim under CO s 275 (issued on 25 July 2019) was served on UBS AG on 23 June 2020. UBS AG at that stage took no objection to the form of the proceedings and proceeded to defend the action:
8.On any view, the writ was served in time and limitation was not pleaded in UBS AG’s defence.[5] However, in the light of two judgments of Ng J in a different liquidation (in which Ps’ firm were Liquidators)[6] Ps became aware of a potential objection to the CO s 275 claim having been commenced by writ instead of by a misfeasance summons in the winding-up as required by rule 58(1) of the Companies Winding-up Rules (“WU r 58(1)”) which relevantly provides:
9.Thus, as a precautionary measure,[7] Ps issued a summons in the winding-up claiming essentially the same relief for fraudulent trading under CO s 275 and served it on UBS AG on 28 May 2021, seeking directions that such summons and the action begun by writ should be consolidated. 10.It was at this point that UBS AG raised the originating process objection. It sought to strike out the writ as having been issued in breach of WU r 58(1).[8] As the argument developed, UBS AG also sought to contend that the claim initiated by the misfeasance summons is time-barred.[9] The question of limitation is very much in dispute. But if UBS AG’s arguments were to succeed, it would rid itself of the entire claim, the writ being set aside as a nullity and the remaining summons being time-barred. C. The Judge’s decision 11.The striking out application succeeded before the Judge[10] who held that WU r 58(1) imposed a mandatory requirement so that commencing a CO s 275 claim by writ was not allowed. He held that claim was therefore a nullity.[11] His Lordship held that it could not be saved by O 2 r 1(3)[12] and O 2 r 2(1)[13] of the Rules of the High Court (“RHC”) for several reasons, the most relevant being that “by virtue of Order 1 rule 2(2),[14] the RHC do not apply to winding up proceedings”[15]. 12.Ps also sought to rely on WU r 209(1) which is pivotally important in the present application. It provides:
13.The Judge, however, held that they could not rely on that rule apparently for the simple reason that they had sought to bring their CO s 275 claim by writ instead of by summons under WU r 58(1):
D. The Court of Appeal’s judgment and UBS AG’s arguments 14.In our view, for reasons corresponding to those provided by the Court of Appeal, the appeal was rightly allowed and UBS AG’s striking out summons rightly dismissed. The contrary is not reasonably arguable. 15.It is not in dispute that under WU r 58(1), a CO s 275 fraudulent trading claim made in the course of a winding-up “shall be made” by summons in the winding-up and that, by commencing the proceedings by writ, Ps failed to comply with that rule. 16.We would also accept that the RHC’s curative provisions (O 2 r 1(3) and O 2 r 2(1)) regarding adoption of an incorrect originating process are not applicable because proceedings relating to the winding-up of companies are excluded by O 1 r 2(2). However, it is important to note that the reason why O 1 r 2(2) excludes such winding-up proceedings is that they are “proceedings in respect of which rules may be made under the enactments specified in the second column of that Table”, ie, the Winding-up Rules. In other words, in cases of incorrect originating process, curative relief is to be sought in the winding-up rules relevant to the appropriate proceedings. 17.Although not applicable, the RHC statutory scheme is instructive. It expressly provides[17] that use of a wrong originating process “shall be treated as an irregularity and shall not nullify the proceedings, any step taken in the proceedings, or any document, judgment or order therein.” Moreover, any challenge to such non-compliance must be “made within a reasonable time and before the party applying has taken any fresh step after becoming aware of the irregularity”, showing that non-compliance can be waived. It is therefore clear that such defects are treated as purely procedural and curable, usually on terms as to costs with any other appropriate directions. Non-compliance does not mean nullity. 18.WU r 209(1) is similarly curative. It provides that “no proceedings under the Ordinance [ie, Cap 32] or the rules shall be invalidated by any formal defect or by any irregularity, unless the court is of opinion that substantial injustice has been caused by the defect or irregularity, and that the injustice cannot be remedied by any order of the court.” 19.With respect, the Judge’s decision that WU r 209(1) was inapplicable simply because Ps had relied on “the inapplicable regime under the RHC to make that Claim”[18] begs the very question at hand: Is the admitted non-compliance by issue of a writ merely a “formal defect or irregularity” coming within WU r 209(1) and therefore curable? 20.Mr Jat Sew-tong SC, appearing for UBS AG, similarly evaded the issue whether WU r 209(1) is applicable by contending, as the premise of his argument, that non-compliance with WU r 58(1) rendered the writ a nullity so that there was nothing capable of being cured by WU r 209(1). That is a question-begging premise that flies in the face of the content, purpose and effect of that rule and is unsustainable. 21.The Court of Appeal’s analysis demonstrates that WU r 209(1) is plainly applicable:
22.UBS AG also sought to argue that “substantial injustice” exists so as to exclude WU r 209(1) principally because granting Ps such relief, would mean that UBS AG is deprived of an accrued limitation defence.[21] 23.That is quite untenable:
24.The other complaint made by UBS AG is that Ps deliberately and knowingly chose the wrong originating process and should, for that reason, be refused relief under WU r 209(1). While the Court of Appeal expressed surprise that Ps had not changed tack sooner (after becoming aware of the point arising in China Medical Technologies, Inc v Wu Xiaodong[25]), it took into account the overall conduct of the proceedings (including UBS AG’s active participation for many months without any WU r 58 objection) and decided that “it would be a disproportionate response to strike out the claim on the ground of the formal defect, in circumstances where the subsequent section 275 summons is arguably time-barred and the application to strike out was issued even later”.[26] E. The leave application 25.The Court of Appeal refused leave to appeal sought on the same grounds as are now being advanced.[27] UBS AG seeks leave, proposing the following Questions:
26.For the reasons given above, we do not consider any of those questions reasonably arguable. As to Question 1, the case plainly falls within WU r 209(1) and the proposition that non-compliance with WU r 58(1) rendered the writ an incurable nullity is indefensible. Questions 2 and 3 are both premised on UBS AG having an accrued limitation defence and that granting curative relief would deprive it of the same – which cannot be made out. 27.Leave is also sought on the “or otherwise” ground based on the criticism that Ps knowingly and deliberately failed to comply with WU r 58(1). The Court of Appeal duly considered this and exercised its discretion to permit reliance on WU r 209(1) taking account of the overall conduct of the proceedings. There is no basis for interfering with that exercise of discretion. 28.In essence, UBS AG seeks to reinstate a decision striking out Ps’ claim on the ground of non-compliance with a rule that ought to have been treated as straightforwardly curable. We accordingly dismissed the application with costs on the basis that none of the points sought to be raised is reasonably arguable.
Mr Jat Sew Tong SC and Ms Elizabeth Cheung, instructed by Herbert Smith Freehills, for the 1st Defendant (Applicant) Mr Charles Sussex SC, instructed by, and Mr Kevin Kee (Solicitor Advocate) of, Karas So LLP, for the 1st & 2nd Plaintiffs (1st & 2nd Respondents) [1] Court of Appeal: CA §8. [2] Cap 32. CO s 275 provides: “If in the course of the winding up of a company it appears that any business of the company has been carried on with intent to defraud creditors of the company or creditors of any other person or for any fraudulent purpose, the court, on the application of the Official Receiver, or the liquidator or any creditor or contributory of the company, may, if it thinks proper so to do, declare that any persons who were knowingly parties to the carrying on of the business in manner aforesaid shall be personally responsible, without any limitation of liability, for all or any of the debts or other liabilities of the company as the court may direct.” [3] CA §§8-9. [4] CA §33. [5] CA §§28-29. [6] China Medical Technologies, Inc v Wu Xiaodong [2020] 1 HKLRD 342; and China Medical Technologies, Inc v Bank of China (Hong Kong) Limited [2021] HKCFI 3042. [7] CA §34. [8] Summons issued on 27 January 2022. [9] Letter from Herbert Smith Freehills to Karas LLP dated 9 September 2021. [10] Anthony Chan J [2022] HKCFI 2215 (“Decision”). [11] Decision §27. [12] Order 2 r 1(3) provides: “The Court shall not wholly set aside any proceedings or the writ or other originating process by which they were begun on the ground that the proceedings ought to have begun by an originating process other than the one employed, but shall instead give directions for the continuation of the proceedings in an appropriate manner.” [13] Order 2 r 2(1) provides: “An application to set aside for irregularity any proceedings, any step taken in any proceedings or any document, judgment or order therein shall not be allowed unless it is made within a reasonable time and before the party applying has taken any fresh step after becoming aware of the irregularity.” [14] Order 1 r 2(2) provides: “These rules shall not have effect in relation to proceedings of the kinds specified in the first column of the following Table (being proceedings in respect of which rules may be made under the enactments specified in the second column of that Table) – ... Proceeding relating to the winding-up of companies – Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap 32), section 296.” [15] CA §15. [16] Decision §16. [17] O 2 r 1(1)-(3). [18] Decision §16. [19] CA §23. [20] [2010] 1 BCLC 72. Insolvency Rules 1986, r 7.55: “No insolvency proceedings shall be invalidated by any formal defect or by any irregularity unless the court before which objection is made considers that substantial injustice has been caused by the defect or irregularity and that the injustice cannot be remedied by any order of the court.” [21] UBS AG skeleton argument §§4, 8(3). [22] 4th Affidavit of Gareth Huw Thomas, filed on behalf of UBS AG, dated 27 January 2022 at §5; CA §29; CA Leave §9. [23] CA §28. [24] Cap 347. Letter Karas LLP to Herbert Smith Freehills dated 12 October 2021. [25] [2020] 1 HKLRD 342; CA §32. [26] CA §35. [27] G Lam and Chow JJA and S T Poon J [2023] HKCA 738. | |||||||||||||||||||||||||||||||||||
Cases cited in this judgment